Latham & Watkins Advises Ascendis Pharma A/S in Public Offering of ADSs

A Bay Area team represented the biopharmaceutical company.

July 08, 2020

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced the pricing of its underwritten public offering of 4,225,352 American Depositary Shares (“ADSs”), which will raise gross proceeds of approximately $600M. 

Latham & Watkins LLP represented Ascendis Pharma A/S in the transaction with a corporate team led by Silicon Valley partner Mark Roeder with associates John Williams, Traci Biedermann, Tess Bloom, and Christopher Lim. Advice was also provided on compensation and benefits matters by Los Angeles partner Sam Weiner with associate Janet Hsu; on tax matters by Silicon Valley partner Jay Metz with associate Lilly Fang; on intellectual property matters by Silicon Valley partner Judith Hasko with associate Gavin Liu; on FDA regulatory matters by Washington DC partner Ben Haas and Brussels partner Hector Armengod with San Francisco counsel Betty Pang and associates Chad Jennings and Lacey Henry.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.